Please assess the completion status of the following clinical trial:

Trial Title: A Study in Japanese Participants With Moderate-to-Severe Psoriasis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Men must agree to use a reliable method of birth control during the study~* Women must agree to use birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment~* Candidates for phototherapy and/or systemic therapy~* Present with chronic psoriasis based on a confirmed psoriasis diagnosis for at least 6 months prior to enrollment~* At least 10% Body Surface Area (BSA) of Psoriasis at screening and at enrollment for participants with plaque psoriasis~* Static Physician Global Assessment (sPGA) score of at least 3 and Psoriasis Area and Severity Index (PASI) score of at least 12 at screening and at enrollment for participants with plaque psoriasis~Exclusion Criteria:~* History of drug-induced psoriasis~* Concurrent or recent use of any biologic agent~* Received systemic psoriasis therapy \[such as psoralen and ultraviolet A (PUVA) light therapy\] or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment for participants with plaque psoriasis~* Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study~* Have participated in any study with interleukin-17(IL-17) antagonists, including ixekizumab~* Serious disorder or illness other than psoriasis~* Serious infection within the last 3 months~* Breastfeeding or nursing (lactating) women~* Clinically significant flare of psoriasis during the 12 weeks prior to enrollment for participants with plaque psoriasis

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 80 mg ixekizumab (Type: EXPERIMENTAL): Administered by two 80 milligram (mg) subcutaneous (SC) injections at Week 0, followed by one 80 mg SC injection per Dosing Regimen 1 up to Week 12. Then administered by one 80 mg SC injection per Dosing Regimen 2 from Week 12 up to Week 52, and for up to 192 weeks following disease relapse occurring during a drug-free period beyond 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).